May 27, 2025?— Laekna (2105.HK)?announced?today that the company will present?two poster?presentations at the 85th?scientific sessions of the American Diabetes Association?(ADA), highlighting its internally discovered ActRII?portfolio. The presentations will feature preclinical data of three monoclonal antibodies?targeting activin type II receptors: LAE102、LAE103 and LAE123, and the first-in-human study results of LAE102, a?monoclonal antibody against ActRIIA. ADA is one of the global leading conferences dedicated to diabetes research, care, and innovation, will take place in?Chicago, USA, from?June 20 to 23?this year.

?

LAE102 is Laekna’s internally discovered monoclonal antibody against ActRIIA. It has shown to increase lean mass and decrease fat mass in pre-clinical models. The Phase I SAD study of LAE102 in China for the treatment of obesity?has been completed, during which single doses of LAE102 resulted in significant and sustained?increase in activin A level, indicating a robust target engagement. The detailed study results will be presented at?ADA 2025. Laekna?has entered into a clinical collaboration with Eli Lilly to accelerate the?clinical development of LAE102 for the treatment of obesity?in the US.

?

Laekna has established a comprehensive portfolio.?Among these, LAE103(an ActRIIB-selective antibody)?and LAE123(a dual-target inhibitor targeting ActRIIA/IIB) have advanced?to IND-enabling studies.?Laekna?is actively advancing these drug candidates?to clinical studies as novel?therapies?for muscle and other disease indications.?

?

Presentation details are as follows:

?

Poster No.1

Abstract Number:?861-P

Title:?Targeting Activin?Type II Receptors—Develop Monoclonal Antibodies LAE102,?LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction

Time:?Sunday, June. 22, 2025, 12:30 p.m. – 13:30?p.m.??CST

Location:?Poster Hall (Hall F1)?McCormick Place Convention Center, Chicago, Illinois

?

Poster No.2

Abstract Number:?2205-LB

Title:?First-in-Human Study to Evaluate Safety,Tolerability, Pharmacokinetics, and Pharmacodynamics of LAE102 in Healthy Volunteers

Time:?Sunday, June. 22, 2025, 12:30 p.m. – 13:30?p.m.??CST

Location:?Poster Hall (Hall F1)?McCormick Place Convention Center, Chicago, Illinois

?

– ?End –

?

Contact Us

IR ?ir@laekna.com

Corporate and Business Development ?BD@laekna.com

?

About Laekna

Stock Code: 2105.HK

?

Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapeutics to patients with metabolic diseases,?cancer and liver fibrosis around the world.

?

As of December 31, 2024, Laekna has initiated seven clinical trials for LAE102, LAE002?(afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers.

?

LAE102 is our internally discovered antibody against ActRIIA. Blocking?Activin-ActRII pathway could promote muscle regeneration and decrease fat mass,?this positions LAE102 as a promising drug candidate for achieving quality weight?control. We’ve obtained IND approvals from the FDA and the CDE for LAE102 in obesity indication and are advancing the Phase I clinical trial in China. In November 2024, Laekna entered into a clinical collaboration agreement with Eli Lilly and Company to support and accelerate global clinical development of LAE102 for the treatment of obesity.

?

Laekna team has accumulated tremendous experiences and deep know-how in the specific field of targeting ActRII receptors and is developing more drug candidates (LAE103 and LAE123), in addition to LAE102, to maximize the value of the target. LAE103 is an ActRIIB-selective antibody and LAE123 is a dual inhibitor against ActRIIA/IIB. Both are our internally discovered antibodies for muscle and other disease indications.

?

In the cancer area, Laekna has built a comprehensive portfolio of drug candidates including LAE002(afuresertib), LAE001 and other seven pre-clinical drug candidates. LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and prostate cancer globally. Laekna has commenced the Phase III clinical trial (AFFIRM-205) for LAE002 in patients with HR+/HER2- breast cancer and the study recruitment is on track.

?

Laekna, Inc. (2105.HK) was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023.

For more information, please visit: http://www.np3h179.cn/??or https://www.linkedin.com/company/74110713/

?

Forward-Looking Statements

This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.